George Dangas (New York, USA) discusses the results of the TWILIGHT-Stent trial, presented at the European Society of Cardiology’s 2021 congress (ESC 2021, 27–30 August, virtual), which examined ticagrelor monotherapy according to stent type.
TWILIGHT-Stent is a sub-study of the TWILIGHT trial, a randomised, placebo-controlled trial, conducted in patients for whom the treating clinician intended to discharge on ticagrelor plus aspirin following successful percutaneous coronary intervention (PCI) with at least one locally approved drug-eluting stent.
“What we can deduce from the study is that there is no red or yellow flag that ticagrelor monotherapy is not as favourable, or has an issue with any broad type of drug-eluting stent used,” Dangas told Cardiovascular News.
